SYS ONLINE
SUPPLEMENT_SCHOLAR
evidence · mechanism · dose
Experimental/Reproductive / HPGResearch peptide

Triptorelin

Long-acting GnRH agonist used to drive a large LH/FSH burst or, with sustained use, suppress them.

Educational explainer of a research peptide. Profiles in this section deliberately omit clinical-trial citations, dosing protocols, and purchase links. Not FDA-approved as a supplement; not a recommendation to use.

Overview

Triptorelin is a synthetic decapeptide GnRH agonist with much greater receptor affinity and resistance to degradation than native GnRH.

Source
  • Synthesized in research laboratories
Forms
  • Subcutaneous or intramuscular injection (depot formulations)

Mechanism of action

Strongly activates GnRH receptors, producing an initial flare of LH/FSH and testosterone, then chronic suppression with sustained dosing.

Pathways
  • · GnRH receptor agonism
  • · Receptor desensitization with sustained exposure
Receptors
  • · GnRH receptor
Hormones
  • · LH
  • · FSH
  • · Testosterone
  • · Estradiol

How it acts on the body

A single dose of triptorelin produces a large LH/FSH spike — useful for diagnostic stimulation testing or as a one-off trigger to restart endogenous testosterone after suppressive cycles. The flare can transiently raise testosterone to supraphysiological levels.

With continuous depot dosing, the same receptor agonism instead desensitizes the pituitary and causes long-term LH/FSH and gonadal hormone suppression — the basis for its oncology use in prostate and certain breast cancers.

Hormonal & endocrine impact

How this peptide is reported to shift specific hormones and signaling molecules. Directionality reflects research literature and preclinical models, not clinical prescribing data.

Projected hormonal trajectory
Illustrative curves derived from reported direction of effect. Not measured patient data.

Curves are schematic shapes (sigmoid for increases/decreases, damped oscillation for modulation/stabilization) anchored to a 100% baseline. They communicate direction and tempo of change reported in research literature — not absolute hormone concentrations.

LH / FSHIncreases
Large acute flare with a single dose.
Testosterone / EstradiolIncreases
Acute downstream surge after flare.
HPG axis (chronic)Decreases
Sustained dosing desensitizes pituitary and suppresses the axis.

Effects on the body

Increases
Acute LH/FSH and testosterone (flare)
Inhibits
HPG axis with chronic depot dosing

Organ system effects

Endocrine

Pituitary GnRH-receptor activation and desensitization.

Reproductive

Strong direct effects on gonadal hormone production.

Reported effects

Drawn from preclinical research, anecdote, and small-scale clinical observation. No evidence grades are assigned — most peptides on this page lack rigorous human trials.

  • Useful diagnostic and oncology applications
  • Can prompt HPG restart in some protocols

Potential side effects

Common
  • · Hot flashes
  • · Injection-site reactions
  • · Mood changes
Rare
  • · Sleep disruption from hot flashes
Serious
  • · Tumor flare in hormone-sensitive cancers without anti-androgen cover

Drug interactions

Anti-androgens
Used together to prevent tumor flare during initiation.
moderate

Pairing context

Often combined with
  • Oncology specialist oversight
    Cancer use is the dominant clinical context.
Avoid combining with
  • Unsupervised use
    Powerful HPG effects with both stimulation and suppression patterns.
Important. Research peptides described here are not FDA-approved supplements. Supplement Scholar does not endorse, recommend, or link to any source for purchase. Consult a qualified clinician before considering any peptide therapy.